Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dichloroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 4/20 | 0.38 |
| ▸ | GABRD | O14764 | 4/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.38 |
| ▸ | GABRE | P78334 | 4/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dichloroacetic Acid SCHEMBL5874380 | 0.90 | LMNA (0.62) | LMNASLC7A5TP53ALDH1A1SLC1A3 | |
| Dichloroacetic Acid SCHEMBL5874312 | 0.86 | — | — | |
| Dichloroacetic Acid SCHEMBL9560991 | 0.83 | LMNA (0.71) | LMNASLC7A5TP53ALDH1A1 | |
| Alanine SCHEMBL15574879 | 0.83 | SLC7A5 (0.53) | LMNASLC7A5TP53ALDH1A1SLC1A3 | |
| Alanine SCHEMBL28556138 | 0.83 | SLC7A5 (0.53) | LMNASLC7A5TP53ALDH1A1SLC1A3 | |
| Dichloroacetic Acid SCHEMBL8427194 | 0.82 | — | — | |
| Dichloroacetic Acid SCHEMBL27654461 | 0.82 | — | — | |
| Dichloroacetic Acid SCHEMBL1331776 | 0.82 | — | — | |
| Dichloroacetic Acid SCHEMBL5307050 | 0.82 | LMNA (1.00) | LMNATP53ALDH1A1MAPT | |
| Dichloroacetic Acid SCHEMBL7777 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220387343-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2022-12-08 | — | — | US | claimed |
| US-20200101025-A1 | Transdermal Drug Delivery System | BioPhysics Pharma, Inc. (US) | 2020-04-02 | — | — | US | claimed |
| JP-1022810-A | — | — | None | — | — | JP | disclosed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023275647-A1 | METHODS AND COMPOSITIONS FOR INCREASING CIRCULATION DURING TREATMENT WITH ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | disclosed |
| US-20230001194-A1 | METHODS AND COMPOSITIONS FOR INCREASING CIRCULATION DURING TREATMENT WITH ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-2352543-A2 | METHODS AND COMPOSITIONS FOR TATTOO REMOVAL | BioChemics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2207536-A1 | TRANSDERMAL DRUG DELIVERY USING AN OSMOLYTE AND VASOACTIVE AGENT | BioChemics, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2010065922-A2 | METHODS AND COMPOSITIONS FOR TATTOO REMOVAL | BIOCHEMICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010034019-A1 | TRANSDERMAL DRUG DELIVERY USING AN OSMOLYTE AND VASOACTIVE AGENT | BIOCHEMICS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100076035-A1 | Transdermal Drug Delivery using an Osmolyte and Vasoactive Agent | BIOCHEMICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| CN-1568956-A | Compound diisopropylamine dichloroacetate powder and injection prreparations | XIAO GUANGCHANG (CN) | 2005-01-26 | — | — | CN | disclosed |
| JP-S6422810-A | SKIN COSMETIC | KANEBO LTD | 1989-01-25 | — | — | JP | disclosed |